Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in

S O Nascif1, M H Senger, J C Ramos-Dias

  • 1Division of Endocrinology, Universidade Federal de São Paulo, UNIFESP/EPM, São Paulo, Brazil.

Journal of Endocrinological Investigation
|December 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behind the Scenes: Radiotherapy technical training through professionals' eyes.

Technical innovations & patient support in radiation oncology·2024
Same author

GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Journal of endocrinological investigation·2003
Same author

GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Journal of endocrinological investigation·2003
Same author

Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients.

Clinical endocrinology·1999
Same author

Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.

Metabolism: clinical and experimental·1997
Same author

Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.

Clinical endocrinology·1997

Thyrotoxicosis impairs growth hormone (GH) response to GHRH and GHRP-6. Reducing T3 levels with iopanoic acid improves this GH response, but it remains suboptimal compared to healthy individuals.

Area of Science:

  • Endocrinology
  • Metabolism

Background:

  • Thyrotoxicosis is characterized by abnormal growth hormone (GH) secretion patterns, including impaired GH response to growth hormone-releasing hormone (GHRH) and a lack of synergistic response to combined GHRH and GH-releasing peptide-6 (GHRP-6).
  • Previous research indicated that reducing circulating triiodothyronine (T3) levels using iopanoic acid enhances the GHRH-induced GH release in thyrotoxic patients.

Purpose of the Study:

  • To investigate the effect of decreased serum T3 levels on the combined GH response to GHRP-6 and GHRH in hyperthyroid patients.
  • To assess whether reducing T3 levels can normalize the GH response to these peptides in thyrotoxicosis.

Main Methods:

  • A study involving 9 hyperthyroid patients and 9 normal subjects.
  • Hyperthyroid patients received treatment with iopanoic acid and propylthiouracil for 15 days to decrease serum T3 levels.

Related Experiment Videos

  • GH response to co-administered GHRP-6 and GHRH was measured before and after treatment.

    • Main Results:

    • Iopanoic acid treatment effectively reduced and normalized serum T3 levels in hyperthyroid patients.
    • The combined GH response to GHRP-6 plus GHRH significantly increased after T3 reduction.
    • Despite enhancement, the GH response in treated hyperthyroid patients remained significantly lower than in normal subjects.

    Conclusions:

    • Acute reduction of circulating T3 levels partially enhances the GH response to GHRP-6 plus GHRH in thyrotoxicosis.
    • The findings suggest that circulating T3 may not play a critical role in the synergistic mechanism of GHRP-6 and GHRH action.
    • Further research is needed to fully elucidate the complex interplay of thyroid hormones and GH regulation.